222 related articles for article (PubMed ID: 18604717)
1. Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems.
Breccia M; Cannella L; Frustaci A; Stefanizzi C; D'Elia GM; Alimena G
Leuk Lymphoma; 2008 Jul; 49(7):1292-6. PubMed ID: 18604717
[TBL] [Abstract][Full Text] [Related]
2. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.
Singh ZN; Post GR; Kiwan E; Maddox AM
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):293-7. PubMed ID: 21658659
[TBL] [Abstract][Full Text] [Related]
3. [Myelodysplastic syndromes--from FAB to WHO classification].
Kotlarek-Haus S; Haus O
Pol Arch Med Wewn; 2005 Nov; 114(5):1128-37. PubMed ID: 16789514
[No Abstract] [Full Text] [Related]
4. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?
Voglová J; Chrobák L; Neuwirtová R; Malasková V; Straka L
Leuk Res; 2001 Jun; 25(6):493-9. PubMed ID: 11337023
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution.
Nösslinger T; Reisner R; Koller E; Grüner H; Tüchler H; Nowotny H; Pittermann E; Pfeilstöcker M
Blood; 2001 Nov; 98(10):2935-41. PubMed ID: 11698274
[TBL] [Abstract][Full Text] [Related]
7. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
8. Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score.
Oscier DG; Worsley A; Darlow S; Figes A; Williams JD; Hamblin TJ
Leuk Res; 1989; 13(9):833-9. PubMed ID: 2796388
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
Onida F; Kantarjian HM; Smith TL; Ball G; Keating MJ; Estey EH; Glassman AB; Albitar M; Kwari MI; Beran M
Blood; 2002 Feb; 99(3):840-9. PubMed ID: 11806985
[TBL] [Abstract][Full Text] [Related]
11. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
Michaux JL; Martiat P
Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification.
Economopoulos T; Stathakis N; Foudoulakis A; Papadoulis N; Dervenoulas J; Papageorgiou E; Anastassiou C; Hadjioannou J; Raptis S
Eur J Haematol; 1987 Apr; 38(4):338-44. PubMed ID: 3609254
[TBL] [Abstract][Full Text] [Related]
14. The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia.
Moon Y; Kim MH; Kim HR; Ahn JY; Huh J; Huh JY; Han JH; Park JS; Cho SR
Ann Lab Med; 2018 Sep; 38(5):481-483. PubMed ID: 29797820
[TBL] [Abstract][Full Text] [Related]
15. Increased peripheral stem cell pool in MDS: an indication of disease progression?
Vehmeyer K; Haase D; Alves F
Leuk Res; 2001 Nov; 25(11):955-9. PubMed ID: 11597730
[TBL] [Abstract][Full Text] [Related]
16. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
17. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
Strupp C; Gattermann N; Giagounidis A; Aul C; Hildebrandt B; Haas R; Germing U
Leuk Res; 2003 May; 27(5):397-404. PubMed ID: 12620291
[TBL] [Abstract][Full Text] [Related]
18. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal.
Breccia M; Latagliata R; Cannella L; Carmosino I; De Cuia R; Frustaci A; Stefanizzi C; Santopietro M; Alimena G
Leuk Res; 2009 Mar; 33(3):391-4. PubMed ID: 18676015
[TBL] [Abstract][Full Text] [Related]
19. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center.
González-Medina I; Bueno J; Torrequebrada A; López A; Vallespí T; Massagué I
Leuk Res; 2002 Sep; 26(9):821-4. PubMed ID: 12127557
[TBL] [Abstract][Full Text] [Related]
20. Re-evaluation of refractory anemia with excess blasts in transformation.
Ohyashiki K; Nishimaki J; Shoji N; Miyazawa K; Kimura Y; Ohyashiki JH
Leuk Res; 2001 Nov; 25(11):933-9. PubMed ID: 11597728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
